AEGLEA BIOTHERAPEUTICS INC's ticker is AGLE and the CUSIP is 00773J103. A total of 3 filers reported holding AEGLEA BIOTHERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is - and the average weighting 8.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $270,504 | +55.3% | 600,455 | 0.0% | 0.00% | – |
| Q1 2023 | $174,131 | +64393.0% | 600,455 | 0.0% | 0.00% | – |
| Q4 2022 | $270 | -99.9% | 600,455 | +52.4% | 0.00% | – |
| Q3 2022 | $207,000 | +4.0% | 394,020 | 0.0% | 0.00% | – |
| Q2 2022 | $199,000 | -87.5% | 394,020 | -43.1% | 0.00% | – |
| Q1 2022 | $1,592,000 | -51.1% | 692,221 | +0.9% | 0.00% | – |
| Q4 2021 | $3,257,000 | -40.6% | 685,745 | -0.6% | 0.00% | -100.0% |
| Q3 2021 | $5,485,000 | +16.3% | 689,997 | +1.8% | 0.00% | 0.0% |
| Q2 2021 | $4,716,000 | -9.5% | 677,726 | +3.0% | 0.00% | 0.0% |
| Q1 2021 | $5,210,000 | +16.8% | 657,870 | +16.0% | 0.00% | 0.0% |
| Q4 2020 | $4,462,000 | +10.7% | 567,013 | -0.3% | 0.00% | 0.0% |
| Q3 2020 | $4,030,000 | -25.2% | 568,458 | -2.4% | 0.00% | 0.0% |
| Q2 2020 | $5,389,000 | +262.7% | 582,644 | +82.6% | 0.00% | – |
| Q1 2020 | $1,486,000 | -68.9% | 319,080 | -49.1% | 0.00% | -100.0% |
| Q4 2019 | $4,784,000 | +99.1% | 626,342 | +100.4% | 0.00% | 0.0% |
| Q3 2019 | $2,403,000 | +17.3% | 312,487 | +4.5% | 0.00% | – |
| Q2 2019 | $2,048,000 | +5.7% | 299,081 | +24.2% | 0.00% | -100.0% |
| Q1 2019 | $1,937,000 | -20.4% | 240,736 | -26.0% | 0.00% | – |
| Q4 2018 | $2,434,000 | +64.9% | 325,194 | +110.8% | 0.00% | – |
| Q3 2018 | $1,476,000 | -5.3% | 154,287 | +4.7% | 0.00% | – |
| Q2 2018 | $1,559,000 | +412.8% | 147,404 | +380.9% | 0.00% | – |
| Q1 2018 | $304,000 | +84.2% | 30,649 | 0.0% | 0.00% | – |
| Q4 2017 | $165,000 | +13.8% | 30,649 | 0.0% | 0.00% | – |
| Q3 2017 | $145,000 | +23.9% | 30,649 | 0.0% | 0.00% | – |
| Q2 2017 | $117,000 | -52.4% | 30,649 | -7.5% | 0.00% | – |
| Q1 2017 | $246,000 | +143.6% | 33,142 | +42.2% | 0.00% | – |
| Q4 2016 | $101,000 | -17.9% | 23,311 | +21.3% | 0.00% | – |
| Q3 2016 | $123,000 | – | 19,219 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Yu Fan | 112,044 | $532,000 | 6.17% |
| Aisling Capital Management LP | 1,691,151 | $8,033,000 | 2.83% |
| Bain Capital Life Sciences Investors, LLC | 2,847,689 | $13,527,000 | 1.07% |
| GREAT POINT PARTNERS LLC | 910,251 | $4,324,000 | 0.96% |
| Samsara BioCapital, LLC | 883,720 | $4,198,000 | 0.81% |
| Sio Capital Management, LLC | 498,500 | $2,368,000 | 0.71% |
| UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO | 245,678 | $1,167,000 | 0.53% |
| Nantahala Capital Management | 2,813,560 | $13,364,000 | 0.47% |
| Altium Capital Management LP | 293,764 | $1,395,000 | 0.38% |
| Lion Point Capital, LP | 300,000 | $1,425,000 | 0.38% |